Comparison of the Effectiveness Metformin for Deceasing Proliferative Marker in Endometrial Cancer Cells
Status:
Completed
Trial end date:
2020-01-07
Target enrollment:
Participant gender:
Summary
Comparison of the effectiveness metformin versus placebo for deceasing proliferative marker
Ki-67 expression in endometrial tumours when given for 4 weeks before hysterectomy in
endometrial cancer cells.